Randomized Controlled Trial of Strain-Specific Probiotic Formulation (Renadyl) in Dialysis Patients

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Natarajan, Ranganathan ^a   Pechenyak, Bohdan ^a   Vyas, Usha ^a   Ranganathan, Pari ^a   Weinberg, Alan ^b   Liang, Peter ^c   Mallappallil, Mary C ^c   Norin, Allen J ^c   Friedman, Eli A ^c   Saggi, Subodh J ^c  

^a Kibow Biotech Inc   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLACEBO; PROBIOTIC AGENT; UREMIC TOXIN; BIOLOGICAL MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; LEUKOCYTE COUNT; NAUSEA; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VENOUS BLOOD; VOMITING; ADULT; AGED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY;

ADULT; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROBIOTICS; QUALITY OF LIFE; RENAL DIALYSIS;

EID: 84930574152     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/568571     Document Type: Article

References (52)

1. J. K. Nicholson, E. Holmes, J. Kinross, et al., "Host-gut microbiota metabolic interactions, " Science, vol. 336, no. 6086, pp. 1262-1267, 2012.
2. C. A. Lozupone, J. I. Stombaugh, J. I. Gordon, J. K. Jansson, and R. Knight, "Diversity, stability and resilience of the human gut microbiota, " Nature, vol. 489, no. 7415, pp. 220-230, 2012.
3. C. Kunz, S. Kuntz, and S. Rudlof f, "Intestinal flora, " Advances in Experimental Medicine and Biology, vol. 639, pp. 67-79, 2009.
4. D. A. Relman, "Learning about who we are, " Nature, vol. 486, pp. 194-195, 2012.
5. S. R. Gill, M. Pop, R. T. DeBoy, et al., "Metagenomic analysis of the human distal gut microbiome, " Science, vol. 312, no. 5778, pp. 1355-1359, 2006.
6. D. N. Frank and N. R. Pace, "Gastrointestinal microbiology enters themetagenomics era, "CurrentOpinion in Gastroenterology, vol. 24, no. 1, pp. 4-10, 2008.
7. S. Abubucker, N. Segata, J. Goll, et al., "Metabolic reconstruction for metagenomic data and its application to the human microbiome, " PLoS Computational Biology, vol. 8, no. 6, Article ID e1002358, 2012.
8. S. Parvez, K. A. Malik, S. A. Ah Kang, and H.-Y. Kim, "Probiotics and their fermented food products are beneficial for health, " Journal of AppliedMicrobiology, vol. 100, no. 6, pp. 1171-1185, 2006.
9. J. M. Kinross, A. W. Darzi, and J. K. Nicholson, "Gut microbiome-host interactions in health and disease, " Genome Medicine, vol. 3, no. 3, article 14, 2011.
10. M. Murthy, "Delineation of beneficial characteristics of effective probiotics, " Journal of the American Medical Association, vol. 3, pp. 38-43, 2000.
11. N. M. de Roos and M. B. Katan, "Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998, "The American Journal of Clinical Nutrition, vol. 71, no. 2, pp. 405-411, 2000.
12. G. V. Zuccotti, F. Meneghin, C. Raimondi, et al., "Probiotics in clinical practice: an overview, " Journal of International Medical Research, vol. 36, supplement 1, pp. 1A-53A, 2008.
13. G. R. Gibson and M. B. Roberfroid, "Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics, " Journal of Nutrition, vol. 125, no. 6, pp. 1401-1412, 1995.
14. M. E. Grams, E. K. H. Chow, D. L. Segev, and J. Coresh, "Lifetime Incidence of CKD stages 3-5 in the United States, " American Journal of Kidney Diseases, vol. 62, no. 2, pp. 245-252, 2013.
15. M. A. Perazella and S. Khan, "Increased mortality in chronic kidney disease: a call to action, " The American Journal of the Medical Sciences, vol. 331, no. 3, pp. 150-153, 2006.
16. O. E. Ayodele and C. O. Alebiosu, "Burden of chronic kidney disease: an international perspective, " Advances in Chronic Kidney Disease, vol. 17, no. 3, pp. 215-224, 2010.
17. CDC FastStats for 2010. Leading Causes of Death in the U. S., http://www. cdc. gov/nchs/fastats/lcod. htm.
18. USRDS Annual Data Report 2012, "Volume 1: Atlas of CKD and Volume 2: Atlas of ESRD, " http://www.usrds.org/.
19. E. Schepers, G. Glorieux, and R. Vanholder, "The gut: the forgotten organ in Uremia?" Blood Purification, vol. 29, no. 2, pp. 130-136, 2010.
20. H. J. Anders, K. Andersen, and B. Stecher, "The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease, " Kidney International, vol. 83, no. 6, pp. 1010-1016, 2013.
21. P. Stenvinkel, "Inflammation in end-stage renal disease: the hidden enemy, " Nephrology, vol. 11, no. 1, pp. 36-41, 2006.
22. S. V. Shah, R. Baliga, M. Rajapurkar, and V. A. Fonseca, "Oxidants in chronic kidney disease, " Journal of theAmericanSociety of Nephrology, vol. 18, no. 1, pp. 16-28, 2007.
23. I. Karamouzis, P. A. Sarafidis, M. Karamouzis, et al., "Increase in oxidative stress but not in antioxidant capacity with advancing stages of chronic kidney disease, " The American Journal of Nephrology, vol. 28, no. 3, pp. 397-404, 2008.
24. N. Ranganathan, B. G. Patel, P. Ranganathan, et al., "In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease, " ASAIO Journal, vol. 52, no. 1, pp. 70-79, 2006.
25. N. Ranganathan, B. Patel, P. Ranganathan, et al., "Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats, " The ScientificWorld Journal, vol. 5, pp. 652-660, 2005.
26. N. Ranganathan, B. Patel, P. Ranganathan, et al., "Probiotics reduces azotemia in Gottingen mini-pigs, " in Proceedings of the 3rd World Congress of Nephrology Poster Presentation, Singapore, June 2005.
27. R. Palmquist, "A preliminary clinical evaluation of kibow biotics?, a probiotic agent, on feline azotemia, " Journal of the American Holistic Medical Association, vol. 24, no. 4, pp. 23-27, 2006.
28. N. Ranganathan, E. A. Friedman, P. Tam, V. Rao, P. Ranganathan, and R. Dheer, "Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada, " CurrentMedical Research and Opinion, vol. 25, no. 8, pp. 1919-1930, 2009.
29. N. Ranganathan, P. Ranganathan, E. A. Friedman, et al., "Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease, " Advances inTherapy, vol. 27, no. 9, pp. 634-647, 2010.
30. L. Vitetta and G. Gobe, "Uremia and chronic kidney disease: the role of the gut microf lora and therapies with pro-and prebiotics, " Molecular Nutrition and Food Research, vol. 57, no. 5, pp. 824-832, 2013.
31. N. Ranganathan, B. Pechenyak, U. Vyas, et al., "Dose escalation, safety and impact of a strain-specific probiotic (Renadyl) on stages III and IV chronic kidney disease patients, " Journal of Nephrology &Therapeutics, vol. 3, article 141, 2013.
32. K. Taki and T. Niwa, "Indoxyl Sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in Chronic Kidney Disease, " Journal of Renal Nutrition, vol. 17, no. 1, pp. 48-52, 2007.
33. A. W. Martinez, N. S. Recht, T. H. Hostetter, and T. W. Meyer, "Removal of P-cresol sulfate by hemodialysis, " Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3430-3436, 2005.
34. S. Y. Velasquez, C. Susal, G. Opelz, L. F. Garcia, and C. M. Alvarez, "Alloantigen-stimulated induction and release of CD30 in patients with end-stage renal failure, " Human Immunology, vol. 73, no. 11, pp. 1102-1108, 2012.
35. T. Shooshtarizadeh, A. Mohammadali, S. Ossareh, and Y. Ataipour, "Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant, " Experimental and Clinical Transplantation, vol. 11, no. 3, pp. 229-233, 2013.
36. H. Akaike, "A new look at the statistical model identification, " IEEE Transaction on Automatic Control, vol. 19, pp. 716-723, 1974.
37. I.-W. Wu, K.-H. Hsu, C.-C. Lee, et al., "P-cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease, " Nephrology Dialysis Transplantation, vol. 26, no. 3, pp. 938-947, 2011.
38. R. Vanholder, G. Glorieux, R. de Smet, and N. Lameire, "New insights in uremic toxins, " Kidney International, Supplement, vol. 63, supplement 84, pp. S10-S13, 2003.
39. A. H. Berg, C. Drechsler, J. Wenger, et al., "Carbamylation of serum albumin as a risk factor for mortality in patients with Kidney failure, " Science Translational Medicine, vol. 5, no. 175, p. 175ra29, 2013.
40. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, "Epidemiology of cardiovascular disease in chronic renal disease, " Journal of the American Society of Nephrology, vol. 9, supplement 12, pp. S16-S23, 1998.
41. E. M. M. Quigley, "Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults, " Nutrition in Clinical Practice, vol. 27, no. 2, pp. 195-200, 2012.
42. U. Vyas and N. Ranganathan, "Probiotics, prebiotics, and synbiotics: gut and beyond, " Gastroenterology Research and Practice, vol. 2012, Article ID872716, 16 pages, 2012.
43. I. Sekirov, S. L. Russell, L. C. M. Antunes, and B. B. Finlay, "Gut microbiota in health and disease, " Physiological Reviews, vol. 90, no. 3, pp. 859-904, 2010.
44. A. Di Cerbo, F. Pezzuto, L. Palmieri, V. Rottigni, T. Iannitti, and B. Palmieri, "Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update, " International Urology and Nephrology, vol. 45, no. 6, pp. 1569-1576, 2013.
45. L. Vitetta, A. W. Linnane, and G. C. Gobe, "From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (Probiotics) mediating reductions of uremic toxin levels via free radical signaling, " Toxins, vol. 5, pp. 2042-2057, 2013.
46. S. Prakash and T. M. S. Chang, "Microencapsulated genetically engineered live E. coliDH5 cells administered orally to maintain normal plasma urea level in uremic rats, " Nature Medicine, vol. 2, no. 8, pp. 883-887, 1996.
47. M. L. Simenhof f, S. R. Dunn, G. P. Zollner, et al., "Biomodulation of the toxic and nutritional e ff ects of small bowel overgrowth in end stage kidney disease using freeze dried L. acidophilus, " Mineral and Electrolyte Metabolism, vol. 22, no. 1-3, pp. 92-96, 1996.
48. S. R. Dunn, M. L. Simenhof f, K. E. Ahmed, et al., "Effect of oral administration of freeze-dried Lactobacillus acidophilus on small bowel bacterial overgrowth inpatientswith endstage kidney disease: reducing uremic toxins and improving nutrition, " International Dairy Journal, vol. 8, no. 5-6, pp. 545-553, 1998.
49. E. Altermann, W. M. Russell, M. A. Azcarate-Peril, et al., "Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 3906-3912, 2005.
50. N. D. Vaziri, J. Wong, M. Pahl, et al., "Chronic kidney disease alters intestinal microbial flora, " Kidney International, vol. 83, no. 2, pp. 308-315, 2013.
51. L. Vitetta and G. Gobe, "Uremia and chronic kidney disease: the role of the gut microf lora and therapies with pro-and prebiotics, " Molecular Nutrition and Food Research, vol. 57, no. 5, pp. 824-832, 2013.
52. P. A. Aronov, F. J. Luo, N. S. Plummer, et al., "Colonic contribution to uremic solutes, " Journal of the American Society of Nephrology, vol. 22, no. 9, pp. 1769-1776, 2011.